- Home
- SEZL vs ARWR Comparison
SEZL vs ARWR Comparison
Compare SEZL & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- ARWR
- Stock Information
- Founded
- SEZL 2016
- ARWR 2003
- Country
- SEZL United States
- ARWR United States
- Employees
- SEZL N/A
- ARWR N/A
- Industry
- SEZL Diversified Financial Services
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- ARWR Health Care
- Exchange
- SEZL Nasdaq
- ARWR Nasdaq
- Market Cap
- SEZL 3.0B
- ARWR 2.5B
- IPO Year
- SEZL N/A
- ARWR 1993
- Fundamental
- Price
- SEZL $81.52
- ARWR $36.64
- Analyst Decision
- SEZL Buy
- ARWR Strong Buy
- Analyst Count
- SEZL 4
- ARWR 8
- Target Price
- SEZL $113.75
- ARWR $47.75
- AVG Volume (30 Days)
- SEZL 827.3K
- ARWR 2.4M
- Earning Date
- SEZL 11-06-2025
- ARWR 11-25-2025
- Dividend Yield
- SEZL N/A
- ARWR N/A
- EPS Growth
- SEZL 146.46
- ARWR N/A
- EPS
- SEZL 2.93
- ARWR N/A
- Revenue
- SEZL $371,794,890.00
- ARWR $572,976,000.00
- Revenue This Year
- SEZL $65.77
- ARWR $21,421.26
- Revenue Next Year
- SEZL $27.29
- ARWR N/A
- P/E Ratio
- SEZL $27.78
- ARWR N/A
- Revenue Growth
- SEZL 92.95
- ARWR 2816.20
- 52 Week Low
- SEZL $24.86
- ARWR $9.57
- 52 Week High
- SEZL $186.74
- ARWR $39.42
- Technical
- Relative Strength Index (RSI)
- SEZL 40.75
- ARWR 73.44
- Support Level
- SEZL $81.84
- ARWR $36.29
- Resistance Level
- SEZL $87.63
- ARWR $39.38
- Average True Range (ATR)
- SEZL 4.60
- ARWR 1.39
- MACD
- SEZL 1.16
- ARWR 0.06
- Stochastic Oscillator
- SEZL 40.49
- ARWR 69.44
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.